SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 7, 2012
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction
(Commission File Number)
(IRS Employer Identification No.)
750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|£||Written communications pursuant to Rule 425 under the Securities Act.|
|£||Soliciting material pursuant to Rule 14a-12 under the Exchange Act.|
|£||Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.|
|£||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.|
Item 2.02. Results of Operations and Financial Condition.
On August 7, 2012, Keryx Biopharmaceuticals, Inc. (“Keryx”) issued a press release announcing its results for the second quarter ended June 30, 2012. Keryx also announced that on Wednesday, August 8, 2012 at 8:30am EST, Keryx will host an investor conference call to discuss its second quarter financial results and provide a business outlook for the remainder of 2012. A copy of such press release is being furnished as Exhibit 99.1 to this report.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Keryx Biopharmaceuticals, Inc.|
|Date: August 7, 2012|
|By:||/s/ James F. Oliviero|
|James F. Oliviero|
|Chief Financial Officer|
INDEX TO EXHIBITS
|99.1||Press Release dated August 7, 2012.|